Role of reduced ADAMTS13 in arterial ischemic stroke: A Pediatric Cohort Study

Annals of Neurology

Volumn 73, Issue 1, 2013, Pages 58-64

  Lambers, Moritz ^a,b   Goldenberg, Neil A ^c   Kenet, Gili ^d   Kirkham, Fenella J ^e   Manner, Daniela ^b   Bernard, Timothy ^c   Mesters, Rolf M ^f   Junker, Ralf ^b   Stoll, Monika ^a   Nowak Göttl, Ulrike ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Children's Hospital Colorado   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BLOOD GROUP; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; SCHOOL CHILD; STATISTICAL SIGNIFICANCE;

ADAM PROTEINS; ADOLESCENT; AGE FACTORS; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; POPULATION SURVEILLANCE; RISK FACTORS; STROKE;

EID: 84873346152     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23735     Document Type: Article

References (38)

1. Mallick AA, O'Callaghan, FJK,. The epidemiology of childhood stroke. Eur J Paed Neurol 2010; 14: 197-205.
2. Kirkham FJ, Prengler M, Hewes DK, Ganesan V,. Risk factors for arterial ischemic stroke in children. J Child Neurol 2000; 15: 299-307.
3. Lanthier S, Carmant L, David M, et al. Stroke in children: the coexistence of multiple risk factors predicts poor outcome. Neurology 2000; 54: 371-378.
4. Kirkham F, Sébire G, Steinlin M, Sträter R,. Arterial ischaemic stroke in children. Review of the literature and strategies for future stroke studies. Thromb Haemost 2004; 92: 697-706.
5. Munot P, Crow YJ, Ganesan V,. Paediatric stroke: genetic insights into disease mechanisms and treatment targets. Lancet Neurol 2011; 10: 264-274.
6. Haywood S, Liesner R, Pindora S, Ganesan V,. Thrombophilia and first arterial ischaemic stroke: a systematic review. Arch Dis Child 2005; 90: 402-405.
7. Nowak-Göttl U, Langer C, Bergs S, et al. Genetics of hemostasis: differential effects of heritability and household components influencing lipid concentrations and clotting factor levels in 282 pediatric stroke families. Environ Health Perspect 2008; 116: 839-843.
8. Kenet G, Lütkhoff LK, Albisetti M, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010; 121: 1838-1847.
9. Dong JF,. Structural and functional correlation of ADAMTS13. Curr Opin Hematol 2007; 14: 270-276.
10. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
11. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203: 767-776.
12. Chauhan AK, Kisucka J, Brill A, et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008; 205: 2065-2074.
13. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761.
14. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
15. George JN,. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.
16. Kaikita K, Soejima K, Matsukawa M, et al. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 2006; 4: 2490-2493.
17. Crawley JT, Lane DA, Woodward M, et al. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008; 6: 583-588.
18. Bongers TN, de Bruijne EL, Dippel DW, et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009; 207: 250-254.
19. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114: 3329-3334.
20. Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010; 115: 1650-1653.
21. Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in Epidemiology (STROBE) Statment: Guidelines for reporting observational studies. PLOS Med 2007; 4: 1623-1627. e296.
22. Williams LS, Garg BP, Cohen M, et al. Subtypes of ischemic stroke in children and young adults. Neurology 1997; 49: 1541-1545.
23. Sträter R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood-a 5-year follow-up study. Lancet 2002; 360: 1540-1545.
24. Wraige E, Pohl KRE, Ganesan V,. A proposed classification for subtypes of arterial ischaemic stroke in children. Dev Med Child Neurol 2005; 47: 252-256.
25. Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92: 121-124.
26. Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-540.
27. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-1029.
28. Austin SK, Starke RD, Lawrie AS, et al. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br J Haematol 2008; 141: 536-544.
29. Vomund AN, Elaine M,., Majerus EM,. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem 2009; 284: 30925-30932.
30. Neuner B, von Mackensen S, Krümpel A, et al. Health-related quality of life in children and adolescents with stroke, self-reports, and parent/proxies reports: cross-sectional investigation. Ann Neurol 2011; 70: 70-78.
31. Kreuz W, Stoll M, Junker R, et al. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study. Arterioscler Thromb Vasc Biol 2006; 26: 1901-1906.
32. Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37: 2672-2677.
33. Hanson E, Jood K, Nilsson S, et al. Association between genetic variation at the ADAMT13 locus and ischemic stroke. J Thromb Haemost 2009; 7: 2147-2148.
34. Levy GG, Nicols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
35. Lotta LA, Garagiola I, Palla R, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31: 11-19.
36. Arning A, Hiersche M, Witten A, et al. A genome wide association study identifies a gene network of ADAMTS genes in the predisposition to pediatric stroke. Blood 2012; in press.
37. Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; 9: 936-944.
38. Shelat SG, Ai J, Zheng XL,. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost 2005; 31: 659-672.